Avzivi® (BAT1706) is Bio-Thera Solution’second FDA approved product in the United States Avzivi® is the second biosimilar researched,developed, and manufactured by a Chinese pharmaceutical company to receive FDAapproval in the United States Guangzhou, China – December 7, 2023 – Bio-TheraSolu...
DetailsBio-Thera Solutions, a global biopharmaceutical company today announced that the China National Drug Administration (CNDA) has accepted for review the Biologics License Application (BLA) for BAT1406, a proposed biosimilar to Humira(adalimumab), which is used to treat patients with rheumatoid arthrit...
July 25, 2018-- Bio-Thera Solutions, a clinical-stage pharmaceutical company, today announced that dosing has begun ina Phase I clinical study to compare the pharmacokinetics and safety of BAT1806, a proposed biosimilar of Actemra ® (tocilizumab), to US-sourced Actemra ® and EU-sourced RoActemra ®...
In March 2018, BAT4306F, the recombinant glycosylation-modified anti-human-CD20 monoclonal antibody solution for injection, approved for phase I clinical trials in China. BAT4306Fis a next generation anti-CD20 monoclonal antibody. The CD20 receptor is a validated drug target with monoclonal antibodi...
